Evidence map›Paper›PMID 42633427›Full record

ReviewPeerJ2026

Research on serine hydroxymethyltransferase 2 mechanisms in malignant tumor development and progression.

Mei Li, Ya Nan Xu, Xiulan Su, Jianxun Wen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mei Li *Center for Clinical Epidemiology Research, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Ya Nan Xu *Center for Clinical Epidemiology Research, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Xiulan SuCenter for Clinical Epidemiology Research, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Jianxun WenPublic Service Center for Medical Research, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SHMT2 (serine hydroxymethyltransferase 2) is a pivotal enzyme in cellular metabolism and is closely associated with the initiation and progression of malignant tumors, garnering significant attention in cancer research and therapy. Aberrant expression of SHMT2 has been observed in various cancers, correlating with tumor aggressiveness and patient prognosis. Functionally, SHMT2 participates in one-carbon metabolism, supplying methyl donors and biosynthetic precursors to support tumor cell proliferation. Additionally, it modulates redox homeostasis, promoting cancer cell survival and progression. SHMT2 also interacts with key signaling pathways, including JAK2/STAT3 and Akt/mTOR, thereby influencing tumor cell growth, invasion, and metastasis. Further elucidation of the molecular mechanisms by which SHMT2 contributes to tumorigenesis may provide critical insights for precision diagnosis, targeted therapy, and prognostic evaluationin oncology.

Indexed as

Glycine HydroxymethyltransferaseNeoplasmsAnimalsCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansSignal TransductionGlycine HydroxymethyltransferaseSHMT protein, humanRegulatory mechanismSHMT2Therapeutic targetTumor growth

Identifiers

PMID42633427
PMCPMC13499534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.